Catenarin
Based on 1 Customer Validation
Catenarin, an anthraquinone compound, inhibits CCR5- and CXCR4-mediated chemotaxis. Catenarin reduces the phosphorylation of mitogen-activated protein kinases (p38 and JNK) and their upstream kinases (MKK6 and MKK7), and calcium mobilization. Catenarin shows anti-inflammatory effect and suppresses leukocyte migration in the diabetes. Catenarin exhibits significant inhibitory effects against Gram-positive bacteria. Catenarin prevents type 1 diabetes (T1D) in nonobese diabetic mice[1][2].
For research use only. We do not sell to patients.
- Purity : 99.21%
- CAS No.: 476-46-0
- Formula: C15H10O6
- Molecular Weight:286.24
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
All Calcium Channel Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Calu-1 | IC50 |
>100 μM
Compound: 11
|
Inhibition of human Calu1 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting
Inhibition of human Calu1 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting
|
[PMID: 11374975] |
| HeLa | IC50 |
>100 μM
Compound: 11
|
Inhibition of human HeLa cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting
Inhibition of human HeLa cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting
|
[PMID: 11374975] |
| K562 | IC50 |
>100 μM
Compound: 11
|
Inhibition of human K562 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting
Inhibition of human K562 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting
|
[PMID: 11374975] |
| Raji | IC50 |
>100 μM
Compound: 11
|
Inhibition of human Raji cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting
Inhibition of human Raji cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting
|
[PMID: 11374975] |
| RAW264.7 | IC50 |
41.32 μM
Compound: 6, Catenarin
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production incubated for 15 mins prior to LPS challenge measured after 20 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production incubated for 15 mins prior to LPS challenge measured after 20 hrs by Griess assay
|
[PMID: 24016057] |
| Vero | IC50 |
>100 μM
Compound: 11
|
Inhibition of african green monkey Vero cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting
Inhibition of african green monkey Vero cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting
|
[PMID: 11374975] |
| WISH | IC50 |
>100 μM
Compound: 11
|
Inhibition of human WISH cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting
Inhibition of human WISH cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting
|
[PMID: 11374975] |
In Vitro
Catenarin (0-2.5 μg/mL, 1 h) inhibits CCR5 (IC50 = 0.24 μg/mL) mediated chemotaxis in JK-EF1α-CCR5 cells and CXCR4 (IC50 = 0.46 μg/mL) mediated chemotaxis in Jurkat cells[1].
Catenarin (1-5 μg/mL, 1 h) inhibits calcium mobilization in CCR5 and CXCR4 pathways in JK-EF1α-CCR5 cells and Jurkat cells[1].
Catenarin (1 μg/mL, 0-15 min) inhibits the activation of MAPK cascades in CCR5 and CXCR4 pathways in JK-EF1α-CCR5 cells and Jurkat cells[1].
Catenarin (1 μg/mL, 1 h) does not affect surface expression of CCR5 and CXCR4 receptors in JK-EF1α-CCR5 cells or Jurkat cells[1].
Catenarin (0.1-0.2 μg/mL, 0-10 h) exhibits significant inhibitory effects against Gram-positive bacteria with a minimum inhibitory concentration (MIC) of 1 μg/mL in complex media and 0.2 μg/mL in synthetic media[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Jurkat cells and JK-EF1α-CCR5 cells
-
Concentration:0.5 μg/mL
-
Incubation Time:8 h
-
Result:Abolished the movement of Jurkat cells and JK-EF1α-CCR5 cells toward SDF-1β and MIP-1β.
Abolished Jurkat cell migration mediated by MKK6 and MKK7.
-
Cell Line:Jurkat cells, JK-EF1α-CCR5 cells and JK-EF1α-CCR5 cells
-
Concentration:1 μg/mL
-
Incubation Time:0, 5, 10, 15 min
-
Result:Inhibited the phosphorylation of the p38 and JNK in JK-EF1α-CCR5 and Jurkat cells in response to MIP-1β and SDF-1β.
Increased the phosphorylation of ERK1/2.
Reduced the phosphorylation of MKK6 in K-EF1α-CCR5 cells triggered by MIP-1β and Jurkat cells triggered by SDF-1β.
Decreased the phosphorylation of MKK7.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female NOD mice (4-30 weeks)[1]
-
Dosage:0.4, 4, and 20 mg/kg
-
Administration:i.p. three times per week for 26 weeks
-
Result:Reduced diabetes in the age-matched mice by 33%, 86%, and 100%.
Prevented T1D in NOD mice to a greater extent than Aspirin (acetylsalicylic acid) (HY-14654).
Showed a marginal-to-modest islet destruction and leukocyte infiltration at 4 mg/kg and over.
Reduced the level of blood glucose and HbA1C at 4 mg/kg and over.
Reduced the number of CD8+ T cells and dendritic cells.
- Kinase activity and phosphorylation assays
- Western Blot
- Cell migration
- Zigmond Chamber Chemotaxis Assay
- Under-Agarose Cell Migration Assay
- Transwell/Boyden Chamber Migration Assay
- Protocol for Kinase activity and phosphorylation assays
- Research Protocol for Inflammation-related Diseases
- Gram Staining of Tissue Sections
- Dunn/Insall Chamber Chemotaxis Assay
- Research Protocol for Metabolic Diseases
Chemical Information
-
CAS No. 476-46-0
-
Appearance Solid
-
Molecular Weight 286.24
-
Formula C15H10O6
-
Color Orange to reddish brown
-
SMILES
O=C1C2=C(C(C3=C(C=C(C)C(O)=C13)O)=O)C(O)=CC(O)=C2
-
Synonyms
Katenarin
-
Structure Classification
-
Initial Source
Conoideocrella krungchingensis
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
In Vitro:
DMSO : 25 mg/mL (87.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shen MY, et al. Catenarin Prevents Type 1 Diabetes in Nonobese Diabetic Mice via Inhibition of Leukocyte Migration Involving the MEK6/p38 and MEK7/JNK Pathways. Evid Based Complement Alternat Med. 2012;2012:982396. [Content Brief]
[2]. Anke H, et al. The anthraquinones of the Aspergillus glaucus group. I. Occurrence, isolation, identification and antimicrobial activity. Arch Microbiol. 1980 Jul;126(3):223-30. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4936 mL | 17.4679 mL | 34.9357 mL | 87.3393 mL |
| 5 mM | 0.6987 mL | 3.4936 mL | 6.9871 mL | 17.4679 mL | |
| 10 mM | 0.3494 mL | 1.7468 mL | 3.4936 mL | 8.7339 mL | |
| 15 mM | 0.2329 mL | 1.1645 mL | 2.3290 mL | 5.8226 mL | |
| 20 mM | 0.1747 mL | 0.8734 mL | 1.7468 mL | 4.3670 mL | |
| 25 mM | 0.1397 mL | 0.6987 mL | 1.3974 mL | 3.4936 mL | |
| 30 mM | 0.1165 mL | 0.5823 mL | 1.1645 mL | 2.9113 mL | |
| 40 mM | 0.0873 mL | 0.4367 mL | 0.8734 mL | 2.1835 mL | |
| 50 mM | 0.0699 mL | 0.3494 mL | 0.6987 mL | 1.7468 mL | |
| 60 mM | 0.0582 mL | 0.2911 mL | 0.5823 mL | 1.4557 mL | |
| 80 mM | 0.0437 mL | 0.2183 mL | 0.4367 mL | 1.0917 mL |